Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 5 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 5 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
OXYTOCIN 5 USP UNITS IN DEXTROSE 5% vs SYNTOCINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, increasing intracellular calcium and stimulating uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to promote milk ejection.
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Induction or augmentation of labor: IV infusion, initial rate 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until adequate contractions; max 20 mU/min. Postpartum hemorrhage: IV infusion 10-40 units in 1000 mL D5W or NS, rate adjusted to control bleeding.
10 units (1 mL) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 mU/min (0.1-0.5 mL/min) titrated to uterine response.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (intravenous); 2–5 minutes (intramuscular); short half-life requires continuous infusion for sustained effect.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Renal (primarily); >99% of infused oxytocin is excreted unchanged in urine; negligible biliary/fecal elimination.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Category C
Category C
Oxytocic
Oxytocic